Related Experiment Video
Updated: Jul 17, 2026

In Vitro Analysis of E3 Ubiquitin Ligase Function
Published on: May 14, 2021
Ligand-induced ubiquitination unleashes LAG3 immune checkpoint function by hindering membrane sequestration of
Yong Jiang1, Anran Dai2, Yuwei Huang3
1School of Life Science and Technology, ShanghaiTech University, Shanghai 201210, China; Key Laboratory of Multi-Cell Systems, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai 200031, China.
Abstract:
Lymphocyte activation gene 3 (LAG3) has emerged as a promising cancer immunotherapy target, but the mechanism underlying LAG3 activation upon ligand engagement remains elusive. Here, LAG3 was found to undergo robust non-K48-linked polyubiquitination upon ligand engagement, which promotes LAG3's inhibitory function instead of causing degradation. This ubiquitination could be triggered by the engagement of major histocompatibility complex class II (MHC class II) and membrane-bound (but not soluble) fibrinogen-like protein 1 (FGL1). LAG3 ubiquitination, mediated redundantly by the E3 ligases c-Cbl and Cbl-b, disrupted the membrane binding of the juxtamembrane basic residue-rich sequence, thereby stabilizing the LAG3 cytoplasmic tail in a membrane-dissociated conformation enabling signaling. Furthermore, LAG3 ubiquitination is crucial for the LAG3-mediated suppression of antitumor immunity in vivo. Consistently, LAG3 therapeutic antibodies repress LAG3 ubiquitination, correlating with their checkpoint blockade effects. Moreover, patient cohort analyses suggest that LAG3/CBL coexpression could serve as a biomarker for response to LAG3 blockade. Collectively, our study reveals an immune-checkpoint-triggering mechanism with translational potential in cancer immunotherapy.
Insights
Lymphocyte activation gene 3 (LAG3) is activated by non-K48-linked polyubiquitination upon ligand binding, enhancing its immune suppression. This mechanism, targeted by therapeutic antibodies, offers new cancer immunotherapy strategies.
Area of Science:
- Immunology
- Molecular Biology
- Cancer Research
Background:
- Lymphocyte activation gene 3 (LAG3) is a key immune checkpoint target in cancer immunotherapy.
- The precise mechanism of LAG3 activation following ligand engagement has remained unclear.
Purpose of the Study:
- To elucidate the molecular mechanism of LAG3 activation upon ligand binding.
- To investigate the role of ubiquitination in LAG3 function and its implications for cancer immunotherapy.
Main Methods:
- Studied LAG3 ubiquitination using biochemical assays and cell-based models.
- Investigated the role of E3 ligases c-Cbl and Cbl-b in LAG3 ubiquitination.
- Analyzed the impact of LAG3 ubiquitination on antitumor immunity in vivo.
- Correlated therapeutic antibody effects with LAG3 ubiquitination levels.
Main Results:
- Ligand engagement triggers non-K48-linked polyubiquitination of LAG3, enhancing its inhibitory function.
- Major histocompatibility complex class II (MHC class II) and membrane-bound fibrinogen-like protein 1 (FGL1) induce LAG3 ubiquitination.
- Ubiquitination, mediated by c-Cbl and Cbl-b, stabilizes the LAG3 cytoplasmic tail, promoting signaling.
- LAG3 ubiquitination is essential for suppressing antitumor immunity in vivo.
- Therapeutic LAG3 antibodies inhibit LAG3 ubiquitination, correlating with checkpoint blockade efficacy.
Conclusions:
- LAG3 activation involves non-K48-linked polyubiquitination, promoting its immune suppressive function.
- This ubiquitination mechanism is critical for LAG3-mediated T-cell suppression and represents a target for cancer immunotherapy.
- LAG3/CBL coexpression may serve as a predictive biomarker for response to LAG3 blockade therapies.
Related Concept Videos
Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Hedgehog Signaling Pathway
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
Amplifying Signals via Enzymatic Cascade
TGF - β Signaling Pathway
GPCR Desensitization

